[1]贺捷,陈万青.2012中国肿瘤登记年报[M].北京:军事医学科学出版社,2012. [2]Al-Batran SE,Hartmann JT,Probst S,et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil,leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie[J]. J Clin Oncol,2008,26(9):1435-1442.DOI:10.1200/JCO.2007.13.9378. [3]Van Cutsem E,Moiseyenko VM,Tjulandin S,et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group[J]. J Clin Oncol,2006,24(31):4991-4997.DOI:10.1200/JCO.2006.06.8429. [4]Koizumi W,Narahara H,Hara T,et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial): a phase III trial[J]. Lancet Oncol,2008,9(3):215-221.DOI:10.1016/S1470-2045(08)70035-4. [5]Ajani JA,Rodriguez W,Bodoky G,et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial[J]. J Clin Oncol,2010,28(9):1547-1553.DOI:10.1200/JCO.2009.25.4706. [6]Yoo CH,Noh SH,Shin DW,et al. Recurrence following curative resection for gastric carcinoma[J]. Br J Surg,2000,87(2):236-242.DOI:10.1046/j.1365-2168.2000.01360.x. [7]Maehara Y,Hasuda S,Koga T,et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer[J]. Br J Surg,2000,87(3):353-357.DOI: 10.1046/j.1365-2168.2000.01358.x. [8]王鑫,金晶,李晔雄,等.局部晚期胃癌根治术复发部位分析及对术后放疗意义的探讨[J].中华放射肿瘤学杂志,2011,20(2):133-141.DOI: 10.3760/cma.j.issn.1004-4221.2011.02.014. [9]Shirasaka T,Shimamoto Y,Ohshimo H,et al. Development of a novel form of an oral 5-fluorouracil derivative(S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators[J]. Anti-Cancer Drugs,1996,7(5):548-557.DOI:10.1097/00001813-199607000-00010. [10]Ueno H,Ioka T,Ikeda M,et al. Randomized phase III study of gemcitabine plus S-1,S-1 alone,or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol,2013,31(13):1640-1648.DOI:10.1200/JCO.2012.43.3680. [11]Bae WK,Hwang JE,Shim HJ,et al. Multicenter phase II study of weekly docetaxel,cisplatin,and S-1(TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck[J/OL]. BMC Cancer,2013,13:102[2014-05-01].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599387/.DOI:10.1186/1471-2407-13-102. [12]Niho S,Ikeda N,Michimae H,et al.Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: thoracic oncology research group study 0809[J]. Br J Cancer,2013,109(3):545-551.DOI: 10.1038/bjc.2013.378. [13]Jin M,Lu H,Li J,et al. Randomized 3-armed phase Ⅲ study of S-1 monotherapy versus S-1/CDDP(SP) versus 5-FU/CDDP(FP) in patients(pts) with advanced gastric cancer(AGC): SC-101study[J/OL].J Clin Oncol,2008,26(15 Suppl 1):4533[2008-05-20].http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/4533?sid=5284f48f-595b-4350-9203-f3a404 d79274. [14]Fujii M,Kim YH,Satoh T,et al. Randomized phase III study of S-1 alone versus S-1 plus docetaxel(DOC) in the treatment for advanced gastric cancer(AGC): the START trial update[J/OL]. J Clin Oncol,2011,29(15 Suppl 1): 4016[2011-05-20].http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/4016?sid=799126b9-e288-4f8f-bc63-1e99f718f037. [15]Narahara H,Iishi H,Imamura H,et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer(study GC0301/TOP-002)[J]. Gastric Cancer,2011,14(1):72-80.DOI:10.1007/s10120-011-0009-5. [16]Sato Y,Takayama T,Sagawa T,et al. Phase II study of S-1,docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer[J]. Cancer Chemother Pharmacol,2010,66(4):721-728.DOI: 10.1007/s00280-009-1215-2. [17]Iwase H,Shimada M,Tsuzuki T,et al. A phase II multi-center study of triple therapy with paclitaxel,S-1 and cisplatin in patients with advanced gastric cancer[J]. Oncology,2011,80(1-2):76-83.DOI: 10.1159/000328746. [18]Kim JY,Do YR,Park KU,et al. Multicenter phase II trial of S-1,paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer[J]. Cancer Chemother Pharmaco,2011,67(3):527-532.DOI: 10.1007/s00280-010-1353-6. [19]Koizumi W,Nakayama N,Tanabe S,et al. A multicenter phase II study of combined chemotherapy with docetaxel,cisplatin,and S-1 in patients with unresectable or recurrent gastric cancer(KDOG 0601)[J]. Cancer Chemother Pharmacol,2012,69(2):407-413.DOI:10.1007/s00280-011-1701-1. [20]Shinichi S,Mitsuru S,Toshiharu Y,et al.Adjuvant chemotherapy for gastric cancer with s-1,an oral fluoropyrimidine[J].N Engl J Med,2007,357(18):1810-1820.DOI:10.1056/NEJMoa072252. [21]Bang Y,Kim YW,Yang HK,et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC): a phase 3 open-label,randomised controlled trial[J]. Lancet,2012,379(9813):315-321.DOI:10.1016/S0140-6736(11)61873-4. [22]Sasako M,Sakuramoto S,Katai H,et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or III gastric cancer[J]. J Clin Oncol,2011,29(33):4387-4393.DOI: 10.1200/JCO.2011.36.5908. [23]Tamura S,Fujitani K,Kimura Y,et al. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage ⅡI gastric cancer patients after curative D2 gastrectomy[J]. Oncology,2011,80(5-6):296-300.DOI: 10.1159/000329090. [24]Fujitani K,Tamura S,Kimura Y,et al. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage ⅡI gastric cancer after curative D2 gastrectomy[J].Gastric Cancer,2014,17(2):348-353.DOI: 10.1007/s10120-013-0273-7. [25]Takahari D,Hamaguchi T,Yoshimura K,et al. Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage ⅡI gastric cancer[J]. Gastric Cancer,2014,17(2):383-386.DOI: 10.1007/s10120-013-0264-8. [26]Iwasaki Y,Sasako M,Yamamoto S,et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers(JCOG0210)[J]. J Surg Oncol,2013,107(7):741-745.DOI: 10.1002/jso.23301. [27]Yoshikawa T,Nakamura K,Tsuburaya A,et al. A phase II study of preoperative chemotherapy with S-1(S) and cisplatin(P) followed by D3 gastrectomy for gastric cancer(GC) with extensive lymph node metastasis(ELM): survival results of JCOG 0405[J/OL]. J Clin Oncol,2011,29(4 Suppl 1): 70[2011-02-01].http://meeting.ascopubs.org/cgi/content/abstract/29/4_suppl/70?sid=f06483 d8-1e28-4bf5-b2b2-e26 d22f77cd2. [28]Hirakawa M,Sato Y,Ohnuma H,et al. A phase II study of neoadjuvant combination chemotherapy with docetaxel,cisplatin,and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair(NER) as potential chemoresistance marker[J]. Cancer Chemother Pharmacol,2013,71(3):789-797.DOI: 10.1007/s00280-013-2073-5. [29]Park I,Ryu MH,Choi YH,et al. A phase II study of neoadjuvant docetaxel,oxaliplatin,and S-1(DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma[J]. Cancer Chemother Pharmacol,2013,72(4):815-823.DOI: 10.1007/s00280-013-2257-z. [30]Inoue K,Nakane Y,Kogire M,et al. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer[J]. Eur J Surg Oncol,2012,38(2):143-149.DOI: 10.1016/j.ejso.2011.11.009. [31]Zhang ZX,Gu XZ,Yin WB,et al.Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia(AGC)—report on 370 patients[J]. Int J Radiat Oncol Biol Phys,1998,42(5):929-934.DOI:10.1016/S0360-3016(98)00280-6. [32]Stahl M,Walz MK,Stuschke M,et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]. J Clin Oncol,2009,27(6):851-856.DOI:10.1200/JCO.2008.17.0506. [33]Tural D,Selcukbiricik F,?zturk MA,et al. The relation between pathological complete response and clinical outcome in patients with rectal cancer[J].Hepatogastroenterology,2013,60(126):1365-137. [34]van Hagen P,Hulshof MC,van Lanschot JJ,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med,2012,366(22):2074-2084.DOI: 10.1056/NEJMoa1112088. [35]Yoshiro S,Tetsuro K,Koshi K,et al.Phase II study for chemoradiotherapy with S-1 and low-dose cisplatin for inoperabe advanced gastric cancer[J].Int J Radiat Oncol Biol Phys,2008,71(1):173-179.DOI:10.1016/j.ijrobp.2007.09.010. [36]Chung MJ,Kim H,Jung YS,et al. A pilot study for preoperative concurrent chemoradiotherapy with S-1 and cisplatin for locally advanced gastric cancer[J]. Hepatogastroenterology,2013,60(122):382-386. [37]Inoue T,Yachida S,Usuki H,et al.Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases[J]. Ann Surg Oncol,2012,19(9):2937-2945.DOI:10.1245/s10434-012-2332-4. [38]Trip AK,Poppema BJ,van Berge Henegouwen MI,et al. Preoperative chemoradiotherapy in locally advanced gastric cancer,a phase I/II feasibility and efficacy study[J]. Radiother Oncol,2014,112(2):284-288.DOI:10.1016/j.radonc. 2014.05.003. [39]Takahashi T,Saikawa Y,Wada N,et al. Phase I study of neoadjuvant chemoradiotherapy as an outpatient setting for patients with resectable advanced gastric cancer[J/OL].J Clin Oncol,2013,31(4 Suppl 1): 84[2013-02-01].http://meeting.ascopubs.org/cgi/content/abstract/31/4_suppl/84?sid=79612 d7c-0faf-436a-96b1-30610c39 dcca. [40]Boku N,Yamamoto S,Fukuda H,et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study[J]. Lancet Oncol,2009,10(11):1063-1069.DOI: 10.1016/S1470-2045(09)70259-1. [41]RH Xu,GP Sun,HS Lu,et al. A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma[J/OL]. J Clin Oncol,2013,31(15 Suppl 1):4025[2013-05-20].http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/4025?sid=e4fc5521-e080-416e-96be-f7c681ba88c9. [42]Yen-Revollo JL,Goldberg RM,McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?[J]. Clin Cancer Res,2008,14(1):8-13.DOI:10.1158/1078-0432.CCR-07-1225. [43]Lee JL,Kang YK,Kang HJ,et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J]. Br J Cancer,2008,99(4):584-590.DOI: 10.1038/sj.bjc.6604536.
2015, Vol. 24 
